Assessment of Platelet-derived GARP in Atherosclerotic Disease

NCT07364058 | Not Yet Recruiting

• 1 other identifier: CAPGAD
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.

Conditions

Atheroma; Carotid Artery; Atheromatosis

Keywords

Atheroma; Atherosclerosis; GARP; LRRC32

Outcome Measures

Primary Outcomes (1)

• GARP Expression in Platelets

  The number of cells/area expressing the GARP protein will be assessed

  Throughout the entire study, approximately during 3 years

Secondary Outcomes (2)

• GARP Expression T Regulating Cells

  Throughout the entire study, approximately during 3 years

• GARP Expression General

  Throughout the entire study, approximately during 3 years

Study Arms (1)

Endarterectomy population

This group includes patients with significant atherosclerotic burden justifying a surgical intervention of carotid or femoral endarterectomy.

Other: Tissue sample and data collection

Interventions

Tissue sample and data collection OTHER

Tissue sample and data collection

Endarterectomy population

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will comprise patients undergoing femoral or carotid endarterectomy in our tertiary care center (Cliniques Universitaires Saint-Luc) for atherosclerotic disease who do not meet exclusion criteria.

You may qualify if:

• Older than 18 years
• Able to give informed consent
• Undergoing carotid or femoral endarterectomy

You may not qualify if:

• Younger than 18 years
• Pregnant
• Dialysis
• Unable to give informed consent

Sponsors & Collaborators

• Université Catholique de Louvain: lead
• Fonds National de la Recherche Scientifique: collaborator

Study Sites (1)

Cliniques Universitaires Saint-Luc

Brussels, 1200, Belgium

Location

Biospecimen

Retention: SAMPLES WITH DNA

The plaques extracted from carotid or femoral endarterectomy will be used or all analysis.

MeSH Terms

Conditions

Carotid Artery Diseases; Atherosclerosis; Plaque, Atherosclerotic

Interventions

Histocompatibility Testing; Data Collection

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Immunologic Tests; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques; Immunologic Techniques; Epidemiologic Methods; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Christophe Beauloye, Medical Degree

  Cliniques universitaires Saint-Luc- Université Catholique de Louvain

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Louis Charki, Medical Degree

CONTACT

+3224362014; louis.charki@uclouvain.be

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 15, 2026
• First Posted: January 23, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): January 1, 2029
• Study Completion (Estimated): January 1, 2029
• Last Updated: January 27, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)